We are live on ! Find out more
CLOS

Compagnie Lombard Odier SCmA Portfolio holdings

AUM $9.25B
1-Year Est. Return 27.04%
This Fund
S&P 500
This Quarter Est. Return
+3.95%
1 Year Est. Return
+27.04%
3 Year Est. Return
+108.78%
5 Year Est. Return
+129.43%
10 Year Est. Return
+503.05%
AUM
$2.82B
AUM Growth
-$67.2M
Cap. Flow
-$96.6M
Cap. Flow %
-3.43%
Top 10 Hldgs %
34.83%
Holding
757
New
65
Increased
148
Reduced
138
Closed
67

Top Buys

Rank Stock Value
1
LYV icon
Live Nation Entertainment
LYV
+$12.7M
2
CB icon
Chubb
CB
+$6.43M
3
CSX icon
CSX Corp
CSX
+$4.66M
4
AGN
Allergan plc
AGN
+$4.39M
5
VPL icon
Vanguard FTSE Pacific ETF
VPL
+$4.22M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$21.2M
2
V icon
Visa
V
+$16M
3
UBS icon
UBS Group
UBS
+$14.6M
4
PANW icon
Palo Alto Networks
PANW
+$8.91M
5
MRK icon
Merck
MRK
+$6.66M

Sector Composition

Rank Sector Weight
1 Healthcare 15.34%
2 Communication Services 14.66%
3 Financials 13.74%
4 Consumer Staples 11.15%
5 Technology 9.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AZN icon
626
AstraZeneca
AZN
$250B
$5K ﹤0.01%
70
BMRN icon
627
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
$5K ﹤0.01%
2,100
-900
-30% -$79.5K
AUMN
628
DELISTED
Golden Minerals Company
AUMN
$5K ﹤0.01%
406
WIN
629
DELISTED
Windstream Holdings Inc
WIN
$5K ﹤0.01%
526
CIE
630
DELISTED
Cobalt International Energy, Inc
CIE
$5K ﹤0.01%
3,571
EVK
631
DELISTED
Ever-Glory International Group, Inc.
EVK
$5K ﹤0.01%
2,000
AMP icon
632
Ameriprise Financial
AMP
$48.8B
$4K ﹤0.01%
30
NLY icon
633
Annaly Capital Management
NLY
$17.4B
$4K ﹤0.01%
75
OCUL icon
634
Ocular Therapeutix
OCUL
$2.02B
$4K ﹤0.01%
700
VANI icon
635
Vivani Medical
VANI
$122M
$4K ﹤0.01%
125
CHTR icon
636
Charter Communications
CHTR
$18.2B
$3K ﹤0.01%
8
-2
-20% -$744
DXC icon
637
DXC Technology
DXC
$1.73B
$3K ﹤0.01%
39
-775
-95% -$55K
MNKD icon
638
MannKind Corp
MNKD
$1.32B
$3K ﹤0.01%
1,559
VIV icon
639
Telefônica Brasil
VIV
$19.2B
$3K ﹤0.01%
212
NBSE
640
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$3K ﹤0.01%
10
AVP
641
DELISTED
Avon Products, Inc.
AVP
$3K ﹤0.01%
1,367
CTIC
642
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3K ﹤0.01%
800
ASIX icon
643
AdvanSix
ASIX
$444M
$2K ﹤0.01%
44
SAN icon
644
Banco Santander
SAN
$210B
$2K ﹤0.01%
295
TZA icon
645
Direxion Daily Small Cap Bear 3x ETF
TZA
$210M
0
STCN
646
DELISTED
Steel Connect, Inc. Common Stock
STCN
$2K ﹤0.01%
86
CB icon
647
CALL
Chubb
CB
$135B
$1K ﹤0.01%
+1,200
New +$174K
NOK icon
648
Nokia
NOK
$52.3B
$1K ﹤0.01%
85
SRS icon
649
ProShares UltraShort Real Estate
SRS
$15.4M
$1K ﹤0.01%
3
TIMB icon
650
TIM SA
TIMB
$8.8B
$1K ﹤0.01%
45

Similar funds

Compagnie Lombard Odier SCmA's Q3 2017 Portfolio in Review

As of Q3 2017, Compagnie Lombard Odier SCmA held 757 positions worth $2.82B, down 2.3% from $2.89B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Compagnie Lombard Odier SCmA withdrew a net $96.6M in Q3 2017, closing 67 positions and reducing 138 holdings. Its most notable exit was Labcorp, an estimated $2.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Compagnie Lombard Odier SCmA opened a new position in Live Nation Entertainment worth $14.3M.

  • Compagnie Lombard Odier SCmA's largest Q3 2017 buy was Live Nation Entertainment: 328,235 shares worth $14.3M.
  • Compagnie Lombard Odier SCmA added most to Chubb in Q3 2017, an estimated $6.43M increase.
  • Compagnie Lombard Odier SCmA's biggest Q3 2017 reduction was AbbVie, cutting an estimated $21.2M.
  • Compagnie Lombard Odier SCmA fully exited Labcorp in Q3 2017, selling an estimated $2.46M.
  • Compagnie Lombard Odier SCmA's ten largest holdings make up 35% of its $2.82B portfolio in Q3 2017.
  • Compagnie Lombard Odier SCmA opened 65 new positions and closed 67 in Q3 2017.
  • Compagnie Lombard Odier SCmA's portfolio value fell 2.3% quarter-over-quarter to $2.82B.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2017, filed 14 Nov 2017.